D3 Bio develops precision medicines targeting unmet needs in oncology and immunology by utilizing a biomarker-driven approach to drug discovery and development. The company focuses on creating therapies that convert life-threatening cancers into manageable chronic conditions, addressing the limitations of existing standard-of-care treatments.
Funding
$62M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers and immunological disorders lack effective treatments, leading to unsatisfactory clinical outcomes for patients. Current standard-of-care approaches may not address the underlying disease mechanisms or may not be tailored to individual patient characteristics. This results in a significant unmet need for more targeted and efficacious therapies.
Solution
D3 Bio is developing precision medicines for oncology and immunology by identifying unmet patient needs and leveraging biomarker-driven drug discovery. The company focuses on creating therapies that target specific disease biomarkers, enabling a personalized approach to treatment. D3 Bio's approach involves identifying the greatest unmet needs in patient care and then guiding the identification of fit-for-purpose science and technology to define their drug development path. Their R&D programs are designed to create a robust portfolio and identify assets with foundational properties for developing future therapies across multiple indications, including both internally developed assets and in-licensed pre-clinical or clinical-stage compounds.
Target Audience
The primary target audience includes patients with cancers and immunological disorders who are not adequately served by existing treatments, as well as the physicians who treat them.
Features
- Biomarker-driven approach to drug discovery and development
- Focus on first-in-class or best-in-class potential therapies
- Pipeline of pre-clinical stage oncology programs targeting immune-pathways or tumor-driving mutations
- Development of therapies designed to convert life-threatening cancers into manageable chronic conditions
- Lead program D3S-001, a second-generation KRAS G12C inhibitor
- Investigational New Drug (IND) clearance from the FDA for D3S-001, currently in Phase 1 clinical trials
- Global rights to all programs